Sin D D, Tu J V
Department of Medicine, Sunnybrook and Women's College Health Science Center, University of Toronto, Toronto, Ontario, Canada.
Chest. 2001 Mar;119(3):720-5. doi: 10.1378/chest.119.3.720.
Despite their proven efficacy, inhaled steroids may be underused in the elderly asthmatic population. The objectives of this study were to determine if inhaled steroids are underused in the elderly asthmatic population, who are at a high risk for rehospitalization and mortality, and to identify certain risk factors that predict lower use of inhaled steroids in this group of patients.
Population-based, retrospective, cohort study using linked data from hospital discharge and outpatient drug databases.
All people > or = 65 years old in Ontario, Canada, who survived an acute exacerbation of asthma between April 1992 and March 1997.
Of the 6,254 patients, 2,495 patients (40%) did not receive inhaled steroid therapy within 90 days of discharge from their initial hospitalization for asthma. Patients > 80 years old were at a greater risk of not receiving inhaled steroid therapy, compared to those 65 to 70 years of age (adjusted odds ratio [OR], 1.23; 95% confidence interval [CI], 1.05 to 1.47). Patients with a Charlson comorbidity index of > or = 3 were also at an increased risk of not receiving inhaled steroid therapy, compared to those having no comorbidities (adjusted OR, 3.45; 95% CI, 1.56 to 7.69). Moreover, receipt of care from a primary-care physician was independently associated with an elevated risk of not receiving inhaled steroid therapy, compared to receipt of care from respirologists/allergists (adjusted OR, 1.35; 95% CI, 1.10 to 1.61).
Forty percent of Ontario patients > or = 65 years old who experienced a recent acute exacerbation of asthma did not receive inhaled steroid therapy near discharge from their initial hospitalization for asthma. Nonreceipt of inhaled steroid therapy was particularly prominent in the older patients with multiple comorbidities. Moreover, those who received care from primary-care physicians were also less likely to receive inhaled steroid therapy, compared to those who received care from specialists.
尽管吸入性类固醇已被证实有效,但在老年哮喘患者中可能未得到充分使用。本研究的目的是确定吸入性类固醇在有再住院和死亡高风险的老年哮喘患者中是否未得到充分使用,并确定预测该组患者吸入性类固醇使用较少的某些风险因素。
基于人群的回顾性队列研究,使用来自医院出院和门诊药物数据库的关联数据。
加拿大安大略省所有年龄≥65岁、在1992年4月至1997年3月期间哮喘急性加重后存活的患者。
在6254例患者中,2495例患者(40%)在因哮喘首次住院出院后90天内未接受吸入性类固醇治疗。与65至70岁的患者相比,80岁以上的患者未接受吸入性类固醇治疗的风险更高(调整后的优势比[OR]为1.23;95%置信区间[CI]为1.05至1.47)。与无合并症的患者相比,Charlson合并症指数≥3的患者未接受吸入性类固醇治疗的风险也增加(调整后的OR为3.45;95%CI为1.56至7.69)。此外,与接受呼吸科医生/过敏症专科医生治疗相比,接受初级保健医生治疗与未接受吸入性类固醇治疗的风险升高独立相关(调整后的OR为1.35;95%CI为1.10至1.61)。
安大略省年龄≥65岁且近期哮喘急性加重的患者中,40%在因哮喘首次住院出院时未接受吸入性类固醇治疗。在患有多种合并症的老年患者中未接受吸入性类固醇治疗尤为突出。此外,与接受专科医生治疗相比接受初级保健医生治疗的患者也不太可能接受吸入性类固醇治疗。